JPRN-jRCT2080223677
Unknown
Phase 3
A Phase III, multi-center, randomized, double-blind, non-inferiority study of Solithromycin versus Cefcapene pivoxil hydrochloride hydrate in patients with sinusitis
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 sitesOctober 13, 2017
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Age: 20 years of age and older (at the time of obtaining informed consents)
- •2\.Gender : Both
- •3\.Inpatient/Outpatient status: Outpatient
- •4\.Signed the informed consent form by patients
- •5\.Sinusitis with clear infection symptoms
Exclusion Criteria
- •1\.Having improvement of clinical symptoms due to target disease by other systemic antibiotics
- •2\.Having a history of allergy to macrolide, penicillin or cephem antibiotics
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 20.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2014-004092-23-PTovartis Pharma Services AG74
Unknown
Phase 3
A Phase III study of Solithromycin in patients with community-acquired pneumoniaJPRN-jRCT2080223384Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
Active, not recruiting
Not Applicable
A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide administered monthly for 24 weeks in subjects with symptomatic endometriosis.EndometriosisMedDRA version: 7Level: LLTClassification code 10014778EUCTR2004-001720-21-GBTakeda Europe R&D Centre Ltd200
Active, not recruiting
Phase 1
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 19.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2014-004092-23-GRovartis Pharma Services AG69
Active, not recruiting
Phase 1
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 20.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860Therapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2014-004092-23-PLovartis Pharma Services AG74